KFF Health News December 2, 2022
Rachana Pradhan

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.

To bring a new drug to market, the FDA requires pharmaceutical firms to perform extensive studies to demonstrate safety and efficacy, which are often expensive and time-consuming to conduct to the agency’s specifications. Getting a drug to market a few months sooner and for less expense than usual can translate into millions in profit for the manufacturer.

That is why a private equity-backed startup like Headlands Research saw an opportunity in creating a network of clinical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Investments, Trends
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
'From Interpretation to Action': Using CGM to Manage T2D
Oncology in 2024: The clinical trial trends reshaping the role of CROs

Share This Article